Literature DB >> 26783729

Dysregulated peripheral endocannabinoid system signaling is associated with cognitive deficits in first-episode psychosis.

Miquel Bioque1, Bibiana Cabrera2, Borja García-Bueno3, Karina S Mac-Dowell3, Carla Torrent4, Pilar A Saiz5, Mara Parellada6, Ana González-Pinto7, Antonio Lobo8, Juan C Leza3, Miguel Bernardo9.   

Abstract

Among etiological explanations for psychosis, several hypotheses involving alterations on the immune/inflammatory system have been proposed. The endocannabinoid system (ECS) is an endogenous neuroprotective, anti-inflammatory system that modulates cognitive processes. Its altered expression has been associated with psychotic disorders. 73 patients with a first episode of psychoses (FEP) and 67 healthy controls were recruited in 5 university centers in Spain. The protein expression of the main peripheral ECS components was determined in peripheral blood mononuclear cells. The cognition function was assessed following the MATRICS consensus. After controlling for potential confounding factors, working memory statistically correlated to the peripheral N-acyl phosphatidylethanolamine phospholipase expression (p = 0.039). The short-term verbal memory correlated to the Diacylglycerol lipase (p = 0.043) and the fatty acid amide hydrolase (p = 0.026) expression. Finally, attention measures correlated to the Monoacylglycerol lipase expression, by means of the CPT-II commissions (p = 0.036) and detectability (p = 0.026) scores. The ECS may regulate the activation of key mediators in immune and inflammatory responses that may be involved in the primary neuronal stress phenomenon that occurs from the onset of psychotic illness. This study points a relationship between the ECS and the cognitive function in early psychosis and suggests the use of some of the ECS elements as biomarkers and/or pharmacological targets for FEP.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarker; Cognition; Endocannabinoid system; First episode psychosis; Schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 26783729     DOI: 10.1016/j.jpsychires.2016.01.002

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  7 in total

1.  Measuring Disturbance of the Endocannabinoid System in Psychosis: A Systematic Review and Meta-analysis.

Authors:  Amedeo Minichino; Morwenna Senior; Natascia Brondino; Sam H Zhang; Beata R Godwlewska; Philip W J Burnet; Andrea Cipriani; Belinda R Lennox
Journal:  JAMA Psychiatry       Date:  2019-09-01       Impact factor: 21.596

Review 2.  Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.

Authors:  Daniela Navarro; Ani Gasparyan; Francisco Navarrete; Abraham B Torregrosa; Gabriel Rubio; Marta Marín-Mayor; Gabriela B Acosta; Maria Salud Garcia-Gutiérrez; Jorge Manzanares
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

3.  The Influence of Oxytocin and Prolactin During a First Episode of Psychosis: The Implication of Sex Differences, Clinical Features, and Cognitive Performance.

Authors:  María Hidalgo-Figueroa; Alejandro Salazar; Cristina Romero-López-Alberca; Karina S MacDowell; Borja García-Bueno; Miquel Bioque; Miquel Bernardo; Mara Parellada; Ana González-Pinto; María Paz García Portilla; Antonio Lobo; Roberto Rodriguez-Jimenez; Esther Berrocoso; Juan C Leza
Journal:  Int J Neuropsychopharmacol       Date:  2022-08-16       Impact factor: 5.678

Review 4.  Endocannabinoid system in psychotic and mood disorders, a review of human studies.

Authors:  Ranjini Garani; Jeremy J Watts; Romina Mizrahi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-09-06       Impact factor: 5.067

Review 5.  Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective.

Authors:  Koby Cohen; Aviv M Weinstein
Journal:  Front Public Health       Date:  2018-06-07

6.  Cannabis use and nonuse in patients with first-episode psychosis: A systematic review and meta-analysis of studies comparing neurocognitive functioning.

Authors:  Teresa Sánchez-Gutiérrez; Belén Fernandez-Castilla; Sara Barbeito; Ana González-Pinto; Juan Antonio Becerra-García; Ana Calvo
Journal:  Eur Psychiatry       Date:  2020-01-31       Impact factor: 5.361

7.  Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls.

Authors:  Rodrigo Ferretjans; Renan P de Souza; Bruna Panizzutti; Pâmela Ferrari; Lucas Mantovani; Salvina M de Campos-Carli; Rafael R Santos; Fernanda C Guimarães; Antonio L Teixeira; Clarissa S Gama; João V Salgado
Journal:  Braz J Psychiatry       Date:  2022 Jan-Feb       Impact factor: 2.697

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.